2 weeks ago
1
The Centre for Cellular and Molecular Platforms (C-CAMP) connected Tuesday announced the enlargement and augmentation of its collaboration with Agilent Technologies, which specialises successful cutting-edge bio-analytics and biotechnology platforms.
C-CAMP said that the 2nd signifier of this concern volition broaden shared entree to precocious analytical and wide spectrometry-based capabilities that volition enactment beingness sciences and therapeutics probe successful India.
The expanded collaboration focuses connected making high‑resolution analytical platforms disposable done C‑CAMP’s shared infrastructure, supporting applications specified arsenic biotherapeutic characterisation, oligonucleotide research, and quantitative biomolecular analysis.
It added that the exemplary is designed to alteration researchers from startups, academia, and manufacture to entree precocious analytical workflows and heavy technological know-how without needing a nonstop superior concern successful specialised instrumentation oregon facilities.
Through this collaboration, Agilent and C‑CAMP purpose to assistance trim introduction barriers and enactment reliable, reproducible subject crossed the probe and improvement continuum.
One of the large milestones from signifier I of this collaboration includes the LC/MS-based characterisation of Liraglutide, a GLP-1 agonist utilized successful diabetes and obesity management, utilizing Agilent’s Mass Spectrometry platform.
“This probe is simply a game-changer for therapeutic peptide development, ensuring compliance with FDA information standards and enhancing cause efficacy,” C‑CAMP said.
Taslimarif Saiyed, manager and CEO, C‑CAMP, said, “In the coming years, we judge specified collaborations volition play a cardinal relation successful enabling exertion improvement and accelerating science-led innovation.”
“Joint efforts volition footwear disconnected with a focused grooming programme designed to equip scientists from startups and manufacture with the skills to measure captious prime attributes (CQAs) successful biopharmaceutical improvement utilizing high- solution LC-MS/MS,” C‑CAMP said.
